Terms: = Colorectal cancer AND CYLD, CYLD1, 1540, ENSG00000083799, USPL2, KIAA0849, CYLDI, CDMT, HSPC057, FLJ31664, FLJ20180, EAC AND Clinical Outcome
5 results:
1. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
Cascinu S; Poli D; Zaniboni A; Lonardi S; Labianca R; Sobrero A; Rosati G; Di Bartolomeo M; Scartozzi M; Zagonel V; Pella N; Banzi M; Torri V
Eur J Cancer; 2019 Apr; 111():1-7. PubMed ID: 30797014
[TBL] [Abstract] [Full Text] [Related]
2. Two histologically colorectal carcinomas subsets from the serrated pathway show different methylome signatures and diagnostic biomarkers.
García-Solano J; Turpin MC; Torres-Moreno D; Huertas-López F; Tuomisto A; Mäkinen MJ; Conesa A; Conesa-Zamora P
Clin Epigenetics; 2018 Nov; 10(1):141. PubMed ID: 30413173
[TBL] [Abstract] [Full Text] [Related]
3. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
[TBL] [Abstract] [Full Text] [Related]
4. Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies.
Wang ZH; Gao QY; Fang JY
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1647-55. PubMed ID: 22610356
[TBL] [Abstract] [Full Text] [Related]
5. Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients.
Abramowitz L; Mathieu N; Roudot-Thoraval F; Lemarchand N; Bauer P; Hennequin C; Mitry E; Romelaer C; Aparicio T; Sobhani I
Aliment Pharmacol Ther; 2009 Aug; 30(4):414-21. PubMed ID: 19392867
[TBL] [Abstract] [Full Text] [Related]
